lunacalcipol   Click here for help

GtoPdb Ligand ID: 11382

Synonyms: CTA-018 | CTA018 | CTA018/MT2832
Compound class: Synthetic organic
Comment: Lunacalcipol (CTA018) is a vitamin D analogue.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 82.98
Molecular weight 474.28
XLogP 5.45
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O[C@H]1C[C@H](O)C(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC=C3[C@@H](C/C=C/S(=O)(=O)C(C)(C)C)C)C)/C1
Isomeric SMILES O[C@H]1C[C@H](O)C(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC=C3[C@@H](C/C=C/S(=O)(=O)C(C)(C)C)C)C)/C1
InChI InChI=1S/C28H42O4S/c1-19(9-8-16-33(31,32)27(3,4)5)24-13-14-25-21(10-7-15-28(24,25)6)11-12-22-17-23(29)18-26(30)20(22)2/h8,11-13,16,19,23,25-26,29-30H,2,7,9-10,14-15,17-18H2,1,3-6H3/b16-8+,21-11+,22-12-/t19-,23-,25+,26+,28-/m1/s1
InChI Key RFQHCLMGLJGZNV-UXXOMSPDSA-N
No information available.
Summary of Clinical Use Click here for help
Lunacalcipol (CTA018) was advanced to clinical evaluation as a treatment for plaque psoriasis, and chronic kidney disease [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00384098 Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis Phase 2 Interventional OPKO Health, Inc.
NCT00742716 Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2 Interventional OPKO Health, Inc.